Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LAMA leads to lower moderate to severe exacerbations: high‐risk population compared with LABA (high certainty).
1 finding from 1 review
Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LAMA showed no clear difference in moderate to severe exacerbations: low‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LAMA showed no clear difference in severe exacerbations: high‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LAMA showed no clear difference in severe exacerbations: low‐risk population compared with LABA (low certainty).
1 finding from 1 review
Pneumonia: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LAMA showed no clear difference in pneumonia: high‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Pneumonia: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LAMA showed no clear difference in pneumonia: low‐risk population compared with LABA (moderate certainty).
1 finding from 1 review
Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in severe exacerbations: low‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Pneumonia: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in pneumonia: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Pneumonia: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in pneumonia: low‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in moderate to severe exacerbations: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in moderate to severe exacerbations: low‐risk population compared with LAMA (low certainty).
1 finding from 1 review
Severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in severe exacerbations: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Exacerbations (OCS) · adults with asthma not well controlled on ICS
LAMA add‐on leads to lower exacerbations requiring oral corticosteroids (OCS) compared with ICS alone (high certainty).
1 finding from 1 review
Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · adults with asthma not well controlled on ICS
1 finding from 1 review
All‐cause serious adverse events 24 weeks · adults with asthma not well controlled on ICS
LAMA add‐on showed no clear difference in all‐cause serious adverse events 24 weeks compared with ICS alone (low certainty).
1 finding from 1 review
Hospital admission (exacerbation) · adults with asthma not well controlled on ICS
LAMA add‐on showed no clear difference in exacerbations requiring hospital admission 24 weeks compared with ICS alone (moderate certainty).
1 finding from 1 review
Change in baseline trough FEV1 · adults with asthma not well controlled on ICS
1 finding from 1 review
Asthma control · adults with asthma not well controlled on ICS
1 finding from 1 review
Any adverse events 24 weeks · adults with asthma not well controlled on ICS
LAMA add‐on showed no clear difference in any adverse events 24 weeks compared with ICS alone (low certainty).
1 finding from 1 review
Mean exacerbations requiring a course of oral corticosteroids · adults with asthma
ICS + LAMA add‐on showed no clear difference in exacerbations requiring a course of OCSa 14 weeks compared with ICS dose increase (low certainty).
1 finding from 1 review